Am J Perinatol 2009; 26(5): 387-392
DOI: 10.1055/s-0029-1214233
© Thieme Medical Publishers

Vitamin E Levels during Early Iron Supplementation in Preterm Infants

Shmuel Arnon1 , 2 , Rivka H. Regev1 , 2 , Sofia Bauer1 , Ruth Shainkin-Kestenbaum1 , Yakov Shiff3 , Yoram Bental3 , 4 , Tzipora Dolfin1 , 2 , Ita Litmanovitz1 , 2
  • 1Department of Neonatology, Meir Medical Center, Kfar Saba, Israel
  • 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • 3Department of Neonatology, Laniado Hospital, Natanya, Israel
  • 4Rappaport Faculty of Medicine, Technion, the Israel Institute of Technology, Haifa, Israel
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. März 2009 (online)

Preview

ABSTRACT

On the basis of preliminary data, this larger bi-institutional continuation trial evaluating the efficacy and safety of early iron supplementation in preterm infants calls attention to the levels of vitamin E, a marker of antioxidant activity, during iron treatment. A total of 116 preterm infants were randomly assigned to receive at 2 or 4 weeks of age (n = 62, n = 54, respectively) 5 mg/kg/d of nonionic iron polymaltose complex concomitantly with a daily dose of 25 IU vitamin E (as dl-α-tocopherol acetate) from 2 weeks of age. Vitamin E (α-tocopherol) levels, iron, ferritin, hemoglobin concentration, and reticulocyte count were recorded from 2 to 8 weeks of age. The morbidities of prematurity associated with free radicals formation were also documented. A gradual increase of α-tocopherol levels within physiological range (0.8 to 3.5 mg/dL) was found in the 2-week and 4-week groups during the study period with no difference among the groups (p > 0.05 for all comparisons). At 8 weeks of age, iron and ferritin levels, hemoglobin concentration, and reticulocyte count were higher in the 2-week group. No correlation was observed between timing of both iron and vitamin E supplement and hemolysis or morbidities associated with prematurity. Thus, treatment of iron with vitamin E supplement at 2 weeks of age is, in our experience, an efficacious and safe treatment for improving anemia in preterm infants.

REFERENCES

Shmuel ArnonM.D. 

Department of Neonatology, Meir Medical Center

Kfar Saba, 44281, Israel

eMail: harnon@netvision.net.il